AptaShape
– The future of health care
In Short
Aptashape technology offers a paradigme shift for disease screening and biomarker identification. Our technology enables population-wide screening for early identification of chronic diseases, saves public health care costs, and allows treatments at an early disease state to the benefit of patients.
We offer: a technology which translates the molecular signature of proteins in bio-fluids into a digital fingerprint by using billions of “chemical antibodies” (aptamers).
Benefits
Unbiased detection
Aptashape detects both known and unknown biomarkers and is sensitive to protein modifications and interactions.
Multiple disease platform
Aptashape can be applied to multiple diseases to develop specific aptamer panels based on unique disease characteristics.
Minimal sample requirement
Aptashape analysis requires only 1µl of blood plasma and can be used with other biofluids e.g. blood, urine, spinal fluids, tears.
Fast and cost-efficient
Aptashape analysis can be performed in less than 24 hours and costs 10-100 times less than mass spectrometry.
High throughput
Aptashape can be scaled to high throughput analyses of samples through automated sequencing platforms.
Biomarker discovery
Disease determining aptamer panels can be applied as a discovery tool for identification of biomarkers, using mass spectrometry.
Publications
Bladder cancer
The APTASHAPE method, developed as part of this study, showcases a novel approach for profiling proteins in plasma using RNA aptamers combined with next-generation sequencing. This innovative diagnostic tool demonstrated over 90% accuracy in differentiating between bladder cancer patients and healthy controls and 83% accuracy in distinguishing early-stage from late-stage tumors. APTASHAPE also identified key proteins associated with bladder cancer, such as Complement C3 and Fibrinogen, emphasizing its potential for biomarker discovery and disease staging. The method holds promise for non-invasive diagnostics and personalized treatment strategies.
COVID-19
The study demonstrates the potential of APTASHAPE technology for unbiased plasma protein profiling to predict mortality in COVID-19 patients. By utilizing RNA aptamer pools, researchers identified predictive aptamers capable of distinguishing COVID-19 plasma from healthy samples. A subset of the predictive aptamers predicted 30-day mortality achieving high accuracy AUC 0.91 and 0.68 in females and males, respectively. Key findings include gender-specific differences and the identification of biomarkers related to the complement system, offering insights into disease severity and personalized treatment opportunities.
Lung cancer
Lung cancer remains the leading cause of cancer-related mortality worldwide, with over 2.2 million cases and approximately 1.8 million deaths reported in 2020. Addressing the urgent need for accurate early-stage detection, we are developing a novel blood-based screening test designed to pre-qualify individuals for low-dose computed tomography (LDCT) screening. Leveraging the APTASHAPE profiling method, this cost-effective and scalable tool has shown promising preliminary results, effectively detecting and stratifying lung cancer patients from a symptomatic control group undergoing diagnostic evaluation.
Meet the team
From sick care to health care
AptaShape
services
We provide laboratory analyses on proteomic level using high-throughput proteomics profiling using RNA-Aptamer libraries with high diversity.
Take a look at what services we can offer you: